Adverse Drug ReactionsPharmacogenetics and adverse drug reactions
Section snippets
History of pharmacogenetics
Pharmacogenetics had its beginning in the 1950s when researchers realised that some adverse drug reactions could be caused by genetically determined variations in enzyme activity. For example, prolonged muscle relaxation after suxamethonium was explained by an inherited deficiency of a plasma cholinesterase, and haemolysis caused by antimalarials was recognised as being caused by inherited variants of glucose-6-phosphate dehydrogenase. Similarly, inherited changes in a patient's ability to
References (29)
- et al.
Polymorphic human cytochrome P450 enzymes; an opportunity for individualized drug treatment
Trends Pharmacol Sci
(1999) Pharmacogenetics and future drug development and delivery
Lancet
(2000)- et al.
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
Lancet
(1999) - et al.
Pharmacogenetics and cancer chemotherapy
Eur J Cancer
(1998) The essence of SNPs
Gene
(1999)- et al.
Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response
Schizophr Res
(1998) - et al.
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies
JAMA
(1998) Genotype or phenotype: the definition of a pharmacogenetic polymorphism
Pharmacogenetics
(1991)Drugs in special patient groups: clinical importance of genomics in drug effects
- et al.
Pharmacogenomics: translating functional genomics into rational therapeutics
Science
(1999)
Molecular mechanisms of genetic polymorphisms of drug metabolism
Annu Rev Pharmacol Toxicol
Cytochrome P4502C9; an enzyme of major importance in human drug metabolism
Br J Clin Pharmacol
Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele
Pharmacogenetics
Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
Clin Pharmacol Ther
Cited by (533)
The effect of alpha-2A adrenergic receptor (ADRA2A) genetic polymorphisms on the depth of sedation of dexmedetomidine: a genetic observational pilot study
2022, Brazilian Journal of Anesthesiology (English Edition)Citation Excerpt :According to recent studies, the individual variability of the effectiveness of a drug can often be associated with genetically determined variations. Especially, the polymorphisms of drug metabolizing targets, carriers, and enzymes can have a significant impact on individual dose-response relationships.14 Likewise, the genomic polymorphisms of ADRA2A can contribute to individual responses to dexmedetomidine.
Polymorphisms in drug-metabolizing enzymes: Challenges and strategies
2022, Biochemistry of Drug Metabolizing Enzymes: Trends and ChallengesGenetic polymorphism of NAT1 in local Pakistani population
2021, Gene ReportsSuperparamagnetic nanoarchitectures: Multimodal functionalities and applications
2021, Journal of Magnetism and Magnetic MaterialsBioenergetics theory and components: Cytochrome P450
2021, Encyclopedia of Biological Chemistry: Third Edition